Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Stantec boosts NCIB share buyback limit to 5,703,349 shares from 2,281,339 shares

Stantec boosts NCIB share buyback limit to 5,703,349 shares from 2,281,339 shares

ReutersReuters2026/08/18 10:45
  • Stantec raised its normal course issuer bid limit to 5,703,349 common shares from 2,281,339, increasing the cap to 5%.
  • The amended buyback starts Aug. 20, 2026, ending no later than March 11, 2027.
  • As of Aug. 17, 2026, 1,667,292 shares were repurchased at a weighted average price of $103.43.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stantec Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180645PRIMZONEFULLFEED9811475) on August 18, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas